Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of Fenebrutinib in Healthy Volunteers
NCT03596632Phase 1Completed
- Sponsor
- Roche
- Start
- Jul 2018
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fenebrutinib in multiple sclerosis (MS), rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), sponsored by Roche. Primary endpoints: Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) and Percentage of the Total Radioactive Dose Administered Excreted from Urine and Feces. Started Jul 2018; status: completed.
02
Drugs
fenebrutinib
03
Conditions
multiple sclerosis (MS)rheumatoid arthritis (RA)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT03596632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03596632.